105 related articles for article (PubMed ID: 38757223)
1. Overexpression of wild-type HRAS drives non-alcoholic steatohepatitis to hepatocellular carcinoma in mice.
Ling C; Liu SS; Wang YY; Huo GT; Yang YW; Xu N; Wang H; Wu Y; Miao YF; Fu R; Zhao YW; Fan CF
Zool Res; 2024 May; 45(3):551-566. PubMed ID: 38757223
[TBL] [Abstract][Full Text] [Related]
2. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
4. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
[TBL] [Abstract][Full Text] [Related]
5. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
Di Maira G; Foglia B; Napione L; Turato C; Maggiora M; Sutti S; Novo E; Alvaro M; Autelli R; Colombatto S; Bussolino F; Carucci P; Gaia S; Rosso C; Biasiolo A; Pontisso P; Bugianesi E; Albano E; Marra F; Parola M; Cannito S
J Pathol; 2022 May; 257(1):82-95. PubMed ID: 35064579
[TBL] [Abstract][Full Text] [Related]
6. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
[TBL] [Abstract][Full Text] [Related]
7. A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride.
Li S; Motiño O; Lambertucci F; Chen H; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Maiuri MC; Kroemer G; Martins I
Methods Mol Biol; 2024; 2769():57-65. PubMed ID: 38315388
[TBL] [Abstract][Full Text] [Related]
8. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
11. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
12. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
[TBL] [Abstract][Full Text] [Related]
14. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
[TBL] [Abstract][Full Text] [Related]
15. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
16. IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models.
Heredia JE; Sorenson C; Flanagan S; Nunez V; Jones C; Martzall A; Leong L; Martinez AP; Scherl A; Brightbill HD; Ghilardi N; Ding N
PLoS One; 2022; 17(9):e0274582. PubMed ID: 36107926
[TBL] [Abstract][Full Text] [Related]
17. Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
Flensted-Jensen M; Oró D; Rørbeck EA; Zhang C; Madsen MR; Madsen AN; Norlin J; Feigh M; Larsen S; Hansen HH
BMC Gastroenterol; 2024 Feb; 24(1):59. PubMed ID: 38308212
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Febbraio MA; Reibe S; Shalapour S; Ooi GJ; Watt MJ; Karin M
Cell Metab; 2019 Jan; 29(1):18-26. PubMed ID: 30449681
[TBL] [Abstract][Full Text] [Related]
19. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
[TBL] [Abstract][Full Text] [Related]
20. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
